Joseph Lyssikatos - Enliven Therapeutics CoFounder Officer
| ELVN Stock | 24.38 1.03 4.05% |
Founder
Joseph Lyssikatos is CoFounder Officer of Enliven Therapeutics
| Age | 59 |
| Address | 6200 Lookout Road, Boulder, CO, United States, 80301 |
| Phone | 720 647 8519 |
| Web | https://www.enliventherapeutics.com |
Joseph Lyssikatos Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joseph Lyssikatos against Enliven Therapeutics stock is an integral part of due diligence when investing in Enliven Therapeutics. Joseph Lyssikatos insider activity provides valuable insight into whether Enliven Therapeutics is net buyers or sellers over its current business cycle. Note, Enliven Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Enliven Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joseph Lyssikatos over three months ago Disposition of 12000 shares by Joseph Lyssikatos of Enliven Therapeutics at 22.8947 subject to Rule 16b-3 | ||
Joseph Lyssikatos over six months ago Disposition of 2123 shares by Joseph Lyssikatos of Enliven Therapeutics at 22.5212 subject to Rule 16b-3 | ||
Joseph Lyssikatos over six months ago Disposition of 10195 shares by Joseph Lyssikatos of Enliven Therapeutics at 16.2974 subject to Rule 16b-3 |
Enliven Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2137) % which means that it has lost $0.2137 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3098) %, meaning that it created substantial loss on money invested by shareholders. Enliven Therapeutics' management efficiency ratios could be used to measure how well Enliven Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of November 2024, Return On Tangible Assets is likely to drop to -0.28. In addition to that, Return On Capital Employed is likely to drop to -0.36. At this time, Enliven Therapeutics' Total Assets are very stable compared to the past year. As of the 30th of November 2024, Other Current Assets is likely to grow to about 13.7 M, while Non Current Assets Total are likely to drop about 3.7 M.Similar Executives
| Found 5 records | FOUNDER Age | ||
| Jun Yoon | Structure Therapeutics American | 46 | |
| MS MBA | Immuneering Corp | 78 | |
| Shay Shemesh | Nuvectis Pharma | 40 | |
| Patrick Baeuerle | Cullinan Oncology LLC | 66 | |
| Enrique Poradosu | Nuvectis Pharma | 57 | |
Management Performance
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.21 |
Enliven Therapeutics Leadership Team
Elected by the shareholders, the Enliven Therapeutics' board of directors comprises two types of representatives: Enliven Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enliven. The board's role is to monitor Enliven Therapeutics' management team and ensure that shareholders' interests are well served. Enliven Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enliven Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Lyssikatos, CoFounder Officer | ||
| Anish PharmD, CoFounder COO | ||
| Helen MD, Chief Officer | ||
| Benjamin Hohl, CFO Development | ||
| Samuel MBA, CEO, CoFounder | ||
| Dr Esq, Chief Development |
Enliven Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enliven Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | 949.76 M | ||||
| Shares Outstanding | 48.86 M | ||||
| Shares Owned By Insiders | 6.39 % | ||||
| Shares Owned By Institutions | 98.74 % | ||||
| Number Of Shares Shorted | 7.07 M | ||||
| Price To Book | 4.30 X | ||||
| EBITDA | (81.93 M) | ||||
| Net Income | (71.58 M) |
Pair Trading with Enliven Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enliven Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enliven Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Enliven Stock
| 0.46 | HLN | Haleon plc | PairCorr |
| 0.42 | ANRO | Alto Neuroscience, | PairCorr |
| 0.4 | BA | Boeing Fiscal Year End 29th of January 2025 | PairCorr |
| 0.35 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.35 | SHG | Shinhan Financial | PairCorr |
The ability to find closely correlated positions to Enliven Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enliven Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enliven Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enliven Therapeutics to buy it.
The correlation of Enliven Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enliven Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enliven Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enliven Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Return On Assets (0.21) | Return On Equity (0.31) |
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.